The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer

@article{Capper2016TheCI,
  title={The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer},
  author={Cameron P. Capper and Jos{\'e} Larios and Matthew J Sikora and Michael D. Johnson and James Michael Rae},
  journal={Breast Cancer Research and Treatment},
  year={2016},
  volume={157},
  pages={23-30}
}
Cytochrome P450 17A1 (CYP17A1) is the requisite enzyme for synthesis of sex steroids, including estrogens and androgens. As such, inhibition of CYP17A1 is a target for inhibiting the growth of hormone-dependent cancers including prostate and breast cancer. Abiraterone, is a first in class potent and selective CYP17A1 inhibitor that has been approved for the treatment of castration-resistant prostate cancer. Given that, androgens are the precursors for estrogen production, it has been proposed… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
2 Citations
43 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 43 references

Similar Papers

Loading similar papers…